[sjg007]

One drug is already FDA approved. They have a clinical trial for lymphoma. Stanford may patent many parts of it, the two drug combo.. depends on the novelty and the formulation, how it's delivered. It also depends on how obvious it is in the patent sense. You might find other researchers and companies who optimize the system as well (e.g. fine tune the checkpoint inhibitor). But these drugs are manufactured already. So it seems safe to say that the research will be done and if it works we will see clinical use.

Also by definition a patent is in the pubic domain (for knowledge) and the publication is of course a public disclosure.

[mft_]

Just for clarity, neither drug is FDA approved in the conventional sense (i.e. not approved to be sold). However, both SD-101 and also various anti-OX40 MAbs are in clinical trials.

Also for clarity (and responding to the concerns of the original questioner) it's highly unlikely that this combination will be patented by anyone - this isn't how patents are used in drug development. Anyone with access to the necessary drugs would --in theory-- be free to open a clinical trial to test this approach.